Journal
CANCER CELL
Volume 27, Issue 4, Pages 435-436Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.014
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
